BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBRadiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of... More in BioWorld Asia. Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
BioWorld: The Daily Biopharmaceutical News Source
WEBThe FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the first to act via a novel mechanism for the serious psychiatric disorder in over 50 years, finally expanding the treatment options beyond dopamine-targeted therapies.
FGFR4 inhibitor BB-102 shows promise for treating solid tumors
WEBApr 15, 2024 — FGFR4 inhibitor BB-102 shows promise for treating solid tumors. Fibroblast growth factor receptor 4 (FGFR4) interacts with its ligand, FGF19, to regulate cell proliferation, differentiation and apoptosis. Strategics tend to invest in med-tech companies they are looking to acquire or could be acquired. Furthermore, companies like Medtronic plc ...
Methinks sets sights on FDA approval after CE mark win for stroke ...
WEBMarch 8, 2023. By Shani Alexander. Methinks Software SL (dba Methinks.AI), a digital health company, is working on the U.S. FDA submission for its artificial intelligence (AI)-based stroke triage software, which will aid in the detection of acute stroke, after recently receiving CE mark certification. BioWorld MedTech Cardiovascular Digital ...
First in a decade: FDA clears Adaptimmune T-cell therapy Tecelra
WEBAug 2, 2024 — A T-cell therapy from Adaptimmune Therapeutics plc has received accelerated approval from the U.S. FDA to treat advanced synovial sarcoma (SS). Tecelra (afamitresgene autoleucel), a CAR T targeting MAGE-A4, is the first engineered T-cell therapy for solid tumors and the first treatment option for the indication in …
Conferences - BioWorld
WEB2 days ago — Discovery and characterization of second-generation oral Mpro inhibitors. Details on the work leading to the discovery of the second-generation SARS-CoV-2 main protease (Mpro) inhibitor PF-7817883 (ibuzatrelvir) were disclosed recently by Pfizer Inc. The drug is in phase II clinical development for the …
| BioWorld
WEBJan 1, 2002 — Toronto, Ontario. Canada M9W 7H4. Phone: 416-644-5100. www.mdsproteomics.com. Frank Gleeson, president and CEO. Majority-owned subsidiary of MDS Inc. Overview. MDS Proteomics Inc. focuses on proteomics-enabled drug discovery using its proteomics systems, supercomputing and drug design competencies to bridge the gap between gene discovery and ...
Cumulus raising $50M, spinning GPR68 small molecules into GIO
WEBAug 29, 2024 — Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up for clinical development, and spinning them into startups, gathers pace. At the same time, Nodus Oncology Ltd., the first spinout created around an acquired asset, has just reached in vivo proof of concept with its lead DNA damage ...
FDA approves Vericel’s Maci for knee cartilage defects
WEBAug 26, 2024 — Vericel Corp.’s Maci for repairing cartilage defects in the knee has been approved by the U.S. FDA via a supplemental biologics license application. Using a patient’s own cells cultured on a porcine collagen membrane, Maci Arthro is delivered arthroscopically and allows for repair of knee cartilage defects up to 4 cm2.
In the clinic for Dec. 17, 2020 | 2020-12-17 | BioWorld
WEBDec. 17, 2020. Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biotheranostics, Neovasc, Pressure Biosciences, Stemina Biomarker Discovery. BioWorld MedTech Briefs In the clinic.